Roche Says Divarasib Cut Death Risk 44% in Phase III Lung Cancer Trial
Roche reported Phase III Krascendo 1 results showing investigational divarasib reduced the risk of death by 44% versus existing KRAS G12C inhibitors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche Says Divarasib Cut Lung Cancer Death Risk 44% in Phase III Trial
Roche said its experimental drug divarasib reduced the risk of death by 44% versus existing treatments in a Phase III study of previously treated patients with KRAS G12C-mutated non-small cell lung cancer.